A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

A Phase I Study to Evaluate Safety, Tolerability, PK, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC176 in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Progressed on at Least Two Prior Systemic Therapies

This clinical trial is evaluating a drug called AC176 in participants with metastatic castration resistant prostate cancer (mCRPC) who have progressed on at least two prior systemic therapies.

The main goals of this study are to:

• Identify the recommended dose of AC176 that can be given safely to participants
• Evaluate the side effects of AC176
• Evaluate pharmacokinetics of AC176
• Evaluate the effectiveness of AC176

Study Overview

• Status: Terminated
• Conditions: Metastatic Castration Resistant Prostate Cancer
• Intervention / Treatment: Drug: AC176

Detailed Description

AC176-001 is a Phase I, first-in-human, open-label, multi-center dose-escalation study of AC176 given as a single agent. The AC176 is an investigational medicinal product that is a potent orally bioavailable Androgen Receptor (AR) degrader studied for the treatment of Metastatic Castration Resistant Prostate Cancer.

• Study Type: Interventional
• Enrollment (Actual): 28
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Accutar Biotechnology; Phone Number: 929-262-0884; Email: medical@accutarbio.com

Study Locations

• United States
  • Colorado
    • Denver, Colorado, United States, 80218
      • Site 02
  • Florida
    • Sarasota, Florida, United States, 34232
      • Site 03
  • Michigan
    • Detroit, Michigan, United States, 48201
      • Site 05
  • Tennessee
    • Nashville, Tennessee, United States, 37203
      • Site 01
  • Texas
    • Dallas, Texas, United States, 75230
      • Site 04

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Males who are at least 18 years-of-age at the time of signature of the informed consent form (ICF)
2. Patients with histological, pathological, or cytological confirmed diagnosis of advanced or mCRPC who have had disease progression per Prostate Cancer Working Group 3(PCWG3) guidance following standard treatment, including approved taxane-based chemotherapy, or who are not amenable (intolerability, patient choice) to standard therapies, or for whom no therapy of proven efficacy exists.

3. Advanced or metastatic disease per PCWG3 guidance documented by either:

   • Positive bone scan (2 lesions) or metastatic lesions on computed tomography (CT)/magnetic resonance imaging (MRI) that can be followed for response.

   Or

   • Prostate-specific antigen (PSA) values with a starting value of ≥1.0 ng/mL that have increased on 3 occasions obtained a minimum of 1 week apart.

4. Patients must have progressed on at least 2 prior approved systemic therapies (in any setting), with at least 1 being abiraterone, or enzalutamide, or apalutamide or darolutamide
5. Patients who have had surgical or medical castration.
6. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 to 1
7. Life expectancy ≥3 months after the start of the treatment according to the Investigator's judgment

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from study entry:

1. Treatment with any of the following:

   • More than 2 lines of chemotherapy
   • Any systemic anti-cancer therapy, chemotherapy, biologic, or hormonal agent from a previous treatment regimen or clinical study within 4 weeks prior to the first dose of study drug. Any systemic small molecules from a previous treatment regimen or clinical study within 2 weeks or 5 half-lives (whichever is longer, not to exceed 4 weeks) prior to the first dose of study drug, except ADT for medical castration purpose.
   • Any investigational agents from a previous clinical study within 4 weeks prior to the first dose of study treatment
   • Radiation therapy (including therapeutic radioisotopes) within 4 weeks prior to first dose of study drug. Radiation for palliation within 2 weeks of study drug. Palliative radiation for the alleviation of pain due to bone metastasis will be allowed during the study
2. With the exception of alopecia and ≤ Grade 2 peripheral neuropathy, any unresolved toxicities from prior therapy greater than the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade 1 at the time of starting study treatment. Note: subjects with chronic Grade 2 toxicities that are asymptomatic or adequately managed with stable medication may be eligible with Sponsor approval
3. Major surgery (excluding placement of vascular access) within 4 weeks of first dose of study drug.
4. Known symptomatic brain metastases requiring steroids (above physiologic replacement doses)
5. Men who plan to father a child while in the study or within 90 days after the last administration of study treatment
6. Any condition that impairs a patient's ability to swallow whole pills. Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of AC176 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea Grade ≥2, malabsorption syndrome)

7. Any of the following cardiac criteria experienced currently or within the last 6 months:

   • Mean resting corrected QT interval (QTc) >470 msec
   • Any clinically important abnormalities (as assessed by the Investigator) in rhythm, conduction, or morphology of resting electrocardiograms (ECGs), e.g., complete left bundle branch block, third-degree heart block
   • Congestive heart failure (New York Heart Association ≥ Grade 2)
   • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years-of-age, or any concomitant medication known to prolong the QT interval
   • Left ventricular ejection fraction (LVEF) <50% or the lower limit of normal of the institutional standard.
8. As judged by the Investigator, any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, uncontrolled diabetes mellitus, active bleeding diatheses, or active infection. Screening for chronic conditions is not required. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: AC176 Dose Escalation as Single Agent; Single agent dose escalation of AC176. AC176 will be given orally (PO) on a 28-day cycle.	Drug: AC176; AC176 will be given orally (PO) on a 28-day cycle.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse events (AEs)/Serious adverse events (SAEs)	Number of adverse events as characterized by type, frequency, seriousness, and relationship to AC176	Through study completion, approximately 24 months
Incidence of dose limiting toxicities (DLTs) from AC176 monotherapy	Number of subjects with DLT	28 days
Number of patients with vital signs abnormalities	Vital signs abnormalities as characterized by type, frequency, severity and timing	Through study completion, approximately 24 months
Incidence of laboratory abnormalities as a measure of safety and tolerability of AC176	Laboratory abnormalities as characterized by type, frequency, severity and timing	Through study completion, approximately 24 months
Incidence of Electrocardiogram (ECG) abnormalities as a measure of safety and tolerability of AC176	Electrocardiogram (ECG) abnormalities such as heart rate, QTcF, PR, RR and QRS intervals	Through study completion, approximately 24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Response Rate(ORR)		Throughout the study, approximately 24 months
Prostate-Specific Antigen (PSA) response rate	PSA response rate per PCWG3	Throughout the study, approximately 24 months
Title: Duration of Response (DoR)		Throughout the study, approximately 24 months
Time-to-Progression (TTP)		Throughout the study, approximately 24 months
Pharmacokinetic Analysis: area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC(0-inf))		20 weeks
Pharmacokinetic Analysis: area under the concentration-time curve over the dosing interval (AUC(0-tau))		20 weeks
Pharmacokinetic Analysis: maximum plasma concentration (Cmax)		20 weeks
Pharmacokinetic Analysis: time to maximum plasma concentration (tmax)		20 weeks
Pharmacokinetic Analysis: terminal elimination half life (t1/2)		20 weeks

Collaborators and Investigators

• Sponsor: Accutar Biotechnology Inc

Study record dates

Study Major Dates

• Study Start (Actual): March 16, 2022
• Primary Completion (Actual): March 5, 2024
• Study Completion (Actual): March 5, 2024

Study Registration Dates

• First Submitted: January 17, 2022
• First Submitted That Met QC Criteria: February 4, 2022
• First Posted (Actual): February 16, 2022

Study Record Updates

• Last Update Posted (Actual): April 1, 2024
• Last Update Submitted That Met QC Criteria: March 28, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Keywords: Phase I; mCRPC; First in Human; Androgen Receptor; AC176; Androgen Receptor Degrader
• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Genital Neoplasms, Male; Prostatic Diseases; Urogenital Diseases; Male Urogenital Diseases; Genital Diseases, Male; Genital Diseases; Prostatic Neoplasms
• Other Study ID Numbers: AC176-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No